Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP452439.RAbCYmpcIIqNbtGaJSM4UodSnT-bmiRgFx0RYlaZr5dJQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP452439.RAbCYmpcIIqNbtGaJSM4UodSnT-bmiRgFx0RYlaZr5dJQ130_assertion type Assertion NP452439.RAbCYmpcIIqNbtGaJSM4UodSnT-bmiRgFx0RYlaZr5dJQ130_head.
- NP452439.RAbCYmpcIIqNbtGaJSM4UodSnT-bmiRgFx0RYlaZr5dJQ130_assertion description "[At the lowest doses, the TGFbeta-RII-mutated and KRAS2-mutated cell line, TOV-21G, and the BRCA2-mutated cell line, TOV-81D, demonstrated a significantly higher sensitivity to cisplatin and gamma-irradiation than the TP53-mutated cell lines, TOV-112D and OV-90.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP452439.RAbCYmpcIIqNbtGaJSM4UodSnT-bmiRgFx0RYlaZr5dJQ130_provenance.
- NP452439.RAbCYmpcIIqNbtGaJSM4UodSnT-bmiRgFx0RYlaZr5dJQ130_assertion evidence source_evidence_literature NP452439.RAbCYmpcIIqNbtGaJSM4UodSnT-bmiRgFx0RYlaZr5dJQ130_provenance.
- NP452439.RAbCYmpcIIqNbtGaJSM4UodSnT-bmiRgFx0RYlaZr5dJQ130_assertion SIO_000772 15258697 NP452439.RAbCYmpcIIqNbtGaJSM4UodSnT-bmiRgFx0RYlaZr5dJQ130_provenance.
- NP452439.RAbCYmpcIIqNbtGaJSM4UodSnT-bmiRgFx0RYlaZr5dJQ130_assertion wasDerivedFrom befree-2016 NP452439.RAbCYmpcIIqNbtGaJSM4UodSnT-bmiRgFx0RYlaZr5dJQ130_provenance.
- NP452439.RAbCYmpcIIqNbtGaJSM4UodSnT-bmiRgFx0RYlaZr5dJQ130_assertion wasGeneratedBy ECO_0000203 NP452439.RAbCYmpcIIqNbtGaJSM4UodSnT-bmiRgFx0RYlaZr5dJQ130_provenance.